For decades cancer drugmakers have taken a more-is-more model when dosing drugs in clinical trials. U.S. regulators want them to reconsider that approach.
Straight from the hood to streets
For decades cancer drugmakers have taken a more-is-more model when dosing drugs in clinical trials. U.S. regulators want them to reconsider that approach.
Leave a Reply